Friday, December 4, 2020 Daily Archives

BioLife invests in viral vector and freeze media tech firms

by

BioLife Solutions has made investments in iVexSol and PanTHERA CryoSolutions, increasing its scope in the cell and gene therapy space. Life science tools firm BioLife Solutions and its partner Casdin Capital have invested a total of $4 million in iVexSol, as part of a $15.2 million Series A financing round, and $2 million in PanTHERA CryoSolution. iVexSol is a Massachusetts firm focused on developing its lentiviral vector (LVV) manufacturing technology platform. The startup claims the platform can produce LVVs at…

December 4, 2020

Atbtherapeutics secures plant-based production of targeted antibodies

by

Atbtherapeutics has struck a deal with CDMO iBio for the manufacture and scale-up of its ‘atbody’ candidates using its plant-based expressions system. The deal, financials of which have not been divulged, will see contract development and manufacturing organization (CDMO) iBio work with atbtherapeutics to industrialize the GMP manufacturing process for atbtherapeutics’ atbodies. ‘atbodies’ are a novel class of biologics developed by Belgium-based biotech atbtherapeutics. They are composed of full-length antibodies, peptide linkers, and toxic peptide payloads, much like an antibody-drug…

December 4, 2020

Keep Your HCPs Under Control

by

When it comes to manufacturing biologics, managing host cell protein (HCP) levels is essential. A robust HCP strategy can help protect both your timeline and budget. Cytiva understands the challenges researchers face in HCP detection, quantification, and removal. We offer an end-to-end solution for HCP management, and our experts will work with you to find the right strategy tailored to your needs. To get started now, check out our knowledge center for expertise and advice on enhancing your HCP strategy.

December 4, 2020

Manufacturing Pluripotent Cell Therapeutics

by

Here we review strategies for gaining Food and Drug Administration (FDA) approval of allogeneic, pluripotent cell therapies. The crux of the discussion is that when developing a cell therapeutic, it is critical to look as much as a decade ahead to when FDA approval will be sought to commercialize the product through a biologics license application (BLA). While this discussion focuses on FDA approval of cell therapies, it is important to acknowledge the vast number of cell therapy clinical efforts…

December 4, 2020

Bayer launches CGT unit on back of Bluerock and AskBio acquisitions

by

Having closed its $2 billion acquisition of Asklepios BioPharmaceutical (AskBio), Bayer has established a cell and gene therapy platform. The Cell and Gene Therapy (C&GT) Platform within Bayer’s Pharmaceuticals division aims to bring various acquisitions, capabilities, and assets together. According to the firm, the unit “will provide an innovation ecosystem within which the different participating partners, whether they be independent companies or strategic collaborators, can operate most effectively. They keep and further develop their passion and biotech spirit, scientific leadership…

December 4, 2020

Opto-Sensor Guided Centrifugation for Efficient, Reagent-Free Cell Separation in a Semi-Automated Closed System

by

This webcast features: Ben Josey, PhD, Field Applications Scientist, Corning Life Sciences The potential for cell-based immunotherapies is moving fast. But some of the processes to develop and manufacture these clinical-grade therapies can slow you down. This Ask the Expert webinar will cover ways you can reduce the manual steps involved in traditional cell processing. Attend to learn more about: Tips to streamline cell separation and formulation of specific cell populations for cell and gene therapy development and manufacturing Ways…

December 4, 2020